Next Article in Journal
GABAergic Input Affects Intracellular Calcium Levels in Developing Granule Cells of Adult Rat Hippocampus
Previous Article in Journal
Abnormal Lysosomal Positioning and Small Extracellular Vesicle Secretion in Arterial Stiffening and Calcification of Mice Lacking Mucolipin 1 Gene
Previous Article in Special Issue
Is Sleep Disruption a Cause or Consequence of Alzheimer’s Disease? Reviewing Its Possible Role as a Biomarker
Open AccessReview

Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis

1
Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
2
Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000 Ljubljana, Slovenia
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(5), 1714; https://doi.org/10.3390/ijms21051714
Received: 26 January 2020 / Revised: 27 February 2020 / Accepted: 29 February 2020 / Published: 3 March 2020
(This article belongs to the Special Issue Peripheral Biomarkers in Neurodegenerative Diseases)
Amyotrophic lateral sclerosis (ALS) is a complex multi-system neurodegenerative disorder with currently limited diagnostic and no therapeutic options. Despite the intense efforts no clinically applicable biomarkers for ALS are yet established. Most current research is thus focused, in particular, in identifying potential non-invasive circulating biomarkers for more rapid and accurate diagnosis and monitoring of the disease. In this review, we have focused on messenger RNA (mRNA), non-coding RNAs (lncRNAs), micro RNAs (miRNAs) and circular RNA (circRNAs) as potential biomarkers for ALS in peripheral blood serum, plasma and cells. The most promising miRNAs include miR-206, miR-133b, miR-27a, mi-338-3p, miR-183, miR-451, let-7 and miR-125b. To test clinical potential of this miRNA panel, a useful approach may be to perform such analysis on larger multi-center scale using similar experimental design. However, other types of RNAs (lncRNAs, circRNAs and mRNAs) that, together with miRNAs, represent RNA networks, have not been yet extensively studied in blood samples of patients with ALS. Additional research has to be done in order to find robust circulating biomarkers and therapeutic targets that will distinguish key RNA interactions in specific ALS-types to facilitate diagnosis, predict progression and design therapy. View Full-Text
Keywords: amyotrophic lateral sclerosis; ALS; circulating biomarkers; circulating RNAs; blood; miRNA; lncRNA; circRNA; mRNA; ceRNET amyotrophic lateral sclerosis; ALS; circulating biomarkers; circulating RNAs; blood; miRNA; lncRNA; circRNA; mRNA; ceRNET
Show Figures

Figure 1

MDPI and ACS Style

Ravnik-Glavač, M.; Glavač, D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020, 21, 1714. https://doi.org/10.3390/ijms21051714

AMA Style

Ravnik-Glavač M, Glavač D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 2020; 21(5):1714. https://doi.org/10.3390/ijms21051714

Chicago/Turabian Style

Ravnik-Glavač, Metka; Glavač, Damjan. 2020. "Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis" Int. J. Mol. Sci. 21, no. 5: 1714. https://doi.org/10.3390/ijms21051714

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop